SPARC concludes enrolment in global Phase 2 study of Vodobatinib in early Parkinson's disease
Vodobatinib is a potential first-in-class, highly selective and brain penetrating c-Abl inhibitor.
Mumbai: Sun Pharma Advanced Research Company Ltd. (SPARC) today announced the completion of enrolment of 506 patients in a global, randomized, doubleblind, placebo-controlled Phase 2 study in patients with early Parkinson's disease evaluating the safety and efficacy of Abl tyrosine kinase inhibition using K0706 (PROSEEK).
"This is a significant milestone for SPARC & Vodobatinib. I would like to express my gratitude to all the patients, caregivers and the physicians associated with PROSEEK." said Anil Raghavan, CEO of SPARC.
PROSEEK is global, randomized, double-blind, placebo-controlled Phase 2 study in patients with early Parkinson's disease evaluating the safety and efficacy of Abl tyrosine kinase inhibition using K0706/SCC-138.
The primary endpoint is the change from baseline to week 40 in the score of the MDS-UPDRS Part III (Movement Disorder Society – Unified Parkinson’s Disease Rating Scale).
The key secondary endpoints include:
• Change from baseline to Week 40 in the sum of the MDS-UPDRS Parts II and III total scores
• Time from baseline to initiation of symptomatic medication
• Change in health-related quality of life as measured by the European quality of life questionnaire
• Change in Clinician global impression of severity
Vodobatinib is a potential first-in-class, highly selective and brain penetrating c-Abl inhibitor. Vodobatinib is being evaluated under multiple clinical trials in patients with Parkinson’s disease, Dementia with Lewy Body and Chronic Myelogenous Leukemia.
Read also: Sun Pharma, SPARC collaborate for commercialization of phenobarbital for injection in US
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.